SCHEMBL3635448

SCHEMBL3635448

CCOc1c(Nc2ccc(Cl)cc2)c(=O)c1=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.73
MAPT P10636 2/20 0.63
GAA P10253 3/20 0.52
CHEK1 O14757 1/20 0.41
MAP4K4 O95819 1/20 0.41
CHEK2 O96017 1/20 0.41
PRKCG P05129 1/20 0.41
PRKACA P17612 1/20 0.41
RPS6KB1 P23443 1/20 0.41
AKT1 P31749 1/20 0.41
FLT4 P35916 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
RPS6KA3 P51812 1/20 0.41
NEK4 P51957 1/20 0.41
CSNK1G2 P78368 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKAA1 Q13131 1/20 0.41
PRKG2 Q13237 1/20 0.41
ROCK1 Q13464 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7916278 0.85 POLB (0.70) POLBMAPTGAACHEK1CHEK2
SCHEMBL12262808 0.84 POLB (0.68) POLBMAPTGAAHPGDALDH1A1
SCHEMBL10131638 0.84 POLB (0.68) POLBMAPTGAAHPGDALDH1A1
SCHEMBL10112748 0.84 POLB (0.68) POLBMAPTGAATP53SMN1; SMN2
SCHEMBL6646189 0.84 POLB (0.68) POLBMAPTGAAALDH1A1ADAMTS5
SCHEMBL6549773 0.83 POLB (0.68) POLBMAPTGAAADAMTS5MEN1
SCHEMBL7555227 0.82 POLB (0.62) POLBMAPTGAAAKT1TP53
SCHEMBL2772692 0.81 POLB (0.49) POLBMAPTCHEK1MAP4K4CHEK2
SCHEMBL24127368 0.81 POLB (0.65) POLBMAPTGAACHEK1CHEK2
SCHEMBL31028729 0.81 POLB (0.60) POLBMAPTGAATP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119325464-A Square amide derivatives as CB1 allosteric modulators 研究三角协会 2025-01-17 CN disclosed
US-9926275-B2 Allosteric modulators of the cannabinoid 1 receptor NORTHEASTERN UNIVERSITY (US) 2018-03-27 US disclosed
US-9926275-B2 Allosteric modulators of the cannabinoid 1 receptor NORTHEASTERN UNIVERSITY (US) 2018-03-27 US disclosed
US-9926275-B2 Allosteric modulators of the cannabinoid 1 receptor NORTHEASTERN UNIVERSITY (US) 2018-03-27 US disclosed
US-20160194284-A1 ALLOSTERIC MODULATORS OF THE CANNABINOID 1 RECEPTOR NORTHEASTERN UNIVERSITY (US) 2016-07-07 US disclosed
US-20160194284-A1 ALLOSTERIC MODULATORS OF THE CANNABINOID 1 RECEPTOR NORTHEASTERN UNIVERSITY (US) 2016-07-07 US disclosed
US-20160194284-A1 ALLOSTERIC MODULATORS OF THE CANNABINOID 1 RECEPTOR NORTHEASTERN UNIVERSITY (US) 2016-07-07 US disclosed
WO-2015027160-A2 ALLOSTERIC MODULATORS OF THE CANNIBINOID 1 RECEPTOR NORTHEASTERN UNIVERSITY (US) 2015-02-26 WO disclosed
US-8901152-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBVIE INC. (US) 2014-12-02 US disclosed
US-20120277223-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBVIE INC. 2012-11-01 US disclosed
US-8242139-B2 Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme ABBOTT LABORATORIES (US) 2012-08-14 US disclosed
EP-2452937-A1 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme Abbott Laboratories (US) 2012-05-16 EP disclosed
EP-2142521-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME Abbott Laboratories (US) 2010-01-13 EP disclosed
US-20080312282-A1 Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme ABBOTT LABORATORIES (US) 2008-12-18 US disclosed
WO-2008134693-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-11-06 WO disclosed
EP-1197485-B1 Cyclobuten-dione derivatives for use in the treatment of artherosclerosis SERVIER LAB (FR) 2004-08-11 EP disclosed
US-6696469-B2 FOR TREATMENT OF DISEASES OR PATHOLOGICAL CONDITIONS IN WHICH ENDOTHELIAL DYSFUNCTION IS KNOWN; ATHEROSCLEROSIS, DYSLIPIDAEMIA, DIABETES LES LABORATOIRES SERVIER (FR) 2004-02-24 US disclosed
US-20020065419-A1 Cyclobutenedione compounds LES LABORATOIRES SERVIER (FR) 2002-05-30 US disclosed
EP-1197485-A1 Cyclobuten-dione derivatives for use in the treatment of artherosclerosis Les Laboratoires Servier (FR) 2002-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194284-A1 ALLOSTERIC MODULATORS OF THE CANNABINOID 1 RECEPTOR CNR1, CNR2, GPR119 POLB 3492/4885MAPT 3562/4885GAA 3239/4885
US-20080312282-A1 Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme DGAT1, DGAT2, LCAT POLB 2206/4885MAPT 2094/4885GAA 109/4885
US-20120277223-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME DGAT1, DGAT2, LCAT POLB 2206/4885MAPT 2094/4885GAA 109/4885
US-20020065419-A1 Cyclobutenedione compounds NR3C2, NR5A1, CYP11B1 POLB 630/4885MAPT 3977/4885GAA 4303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.